miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
复制标题
DOI：
10.1002/ddr.21266
复制
发表时间：
2015-09
影响因子：
3.8
通讯作者：
Mangone M
中科院分区：
文献类型：
--
作者：
Kotagama K;Chang Y;Mangone M
慢性粒细胞白血病（CML）是一种骨髓增生性肿瘤，其特征通常是致癌蛋白BCR-ABL酪氨酸激酶的组成性表达。针对断裂点簇区域ABL的酪氨酸激酶抑制剂（TKI）是大多数CML患者的一线治疗药物，并显著改善了CML的预后。然而，一些CML患者对TKI治疗无反应，并且显着比例的初始反应患者产生耐药性。几种分子途径与TKI治疗的耐药性相关，然而，产生耐药性的确切机制仍不明确。最近，microRNA（miRNAs）已被牵连在CML的进展和耐药的发展TKI治疗的基础上，其重要的调节功能，在细胞内稳态，和在许多白血病亚型的起始和进展中观察到的失调。在这篇综述中，我们总结了一些关于miRNA在CML中的主要发现，以及它们作为诊断、疾病进展和药物敏感性的生物标志物的相关性。
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is frequently characterized by the constitutive expression of the oncogenic protein BCR-ABL tyrosine kinase. Tyrosine kinase inhibitors (TKIs) targeting breakpoint cluster region-ABL are the first-line therapy for most CML patients and have drastically improved the prognosis of CML. However, some CML patients are unresponsive to TKI treatment, and a notable proportion of initially responsive patients develop drug resistance. Several molecular pathways have been correlated with resistance to TKI treatment, however, the exact mechanism of developing drug resistance remains ambiguous. Recently, microRNAs (miRNAs) have been implicated in the progression of CML and the development of resistance to TKI treatment based on their important regulatory function in cell homeostasis, and the deregulation observed in the initiation and progression of many leukemia subtypes. In this review, we summarize some of the major discoveries regarding miRNAs in CML, and their relevance as biomarkers for diagnosis, disease progression, and drug sensitivity.